Moberg Pharma provides update on timeline for MOB-015
STOCKHOLM, November 8th 2017, Moberg Pharma AB (OMX: MOB) today announced an updated timeline for patient recruitment to the ongoing Phase 3 studies for MOB-015, with recruitment in the North American study expected to be completed during the summer 2018 and recruitment in the European study expected to be completed in the second half of 2018.Recruitment to the Phase 3 studies for MOB-015, a proprietary topical formulation of terbinafine for the treatment of onychomycosis, is underway simultaneously in North America and Europe. However, a significantly higher screening failure rate than